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Abstract
Small-sized (~65 nm) doxorubicin (Dox)-loaded polymeric nanoparticles (PNPs) were modified 
with oligonucleotides to form colloidally stable Dox-loaded polymeric spherical nucleic acid 
(Dox-PSNA) nanostructures in biological media. The nucleic acid shell facilitates the cellular 
uptake of Dox-PSNA, resulting in in-vitro cytotoxicity against SKOV3 cancer cells.
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Polymeric nanoparticles (PNPs) prepared from amphiphilic ROMP block copolymers 
(ROMP = ring-opening metathesis polymerization) represent a versatile class of 
multifunctional nanoconstructs for biodetection,1,2 imaging,3 and drug delivery.4,5 In 
particular, the ease with which these nanoparticles can be surface-functionalized2 with a 
multitude of biologically active entities2,6 has shown promise in many drug delivery 
applications.5,7,8 Previously, we reported that ROMP-based doxorubicin-loaded PNPs can be 
modified with cationic surface moieties post-assembly to improve their stability in buffered 
media and in vitro cellular uptake.7 However, the large diameters of these particles (~100–
200 nm) may limit their cellular uptake9 and tumor penetration when delivered in vivo.10,11 
Thus, we set out to improve the bioavailability of the doxorubicin-loaded PNP platform by 
reducing nanoparticle size and covalently modifying the surface with negatively charged 
oligonucleotides, which have been shown to promote higher cellular uptake.12 Since sub-100 
nm-sized nanoparticles have been shown to exhibit increased cellular uptake and better 
penetration into tumor tissue,13,14 these two modifications may allow for extended stability 
under physiologically relevant conditions and should enhance overall efficacy for in vivo 
applications.
The high-density surface modification of nanoparticles with oligonucleotides results in a 
three-dimensional architecture known as a spherical nucleic acid (SNA).12 The dense 
oligonucleotide shells in SNAs have been shown to stabilize a broad range of nanoparticle 
cores–from inorganic Au,15 Ag,16 and silica17 ones to organic structures such as ultra-small 
liposomes,18 proteins,19 and polymers20,21–under physiological conditions via electrostatic 
repulsion.18 The SNA architecture also promotes superior cellular internalization for the 
nanoparticle cores over PEG-functionalized analogs22 and linear nucleic acids,23 given its 
ability to bind to cellular membrane-bound scavenger receptors,23 which facilitate cellular 
internalization via endosomal pathways.12,24 As a result, SNA structures have been utilized 
in a wide variety of applications spanning biodetection,22 gene regulation25, drug 
delivery,26–28 and immunomodulation.12,29 By covalently modifying small (sub-100 nm) 
doxorubicin-loaded PNPs with oligonucleotides (Scheme 1), we show herein that the 
resulting doxorubicin-loaded polymeric SNA (Dox-PSNA) structures are stable under 
physiologically relevant conditions, are capable of active cellular internalization, and exhibit 
cytotoxicity with respect to SKOV-3 ovarian cancer cells. While the potency of these Dox-
PSNA nanoparticles is comparable to that of the free drug, they should not be prone to the 
renal clearance issues that plague small molecules.30
MATERIALS AND METHODS
Materials and Instrumentation
Please see SI, Section S1
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Synthesis of block copolymer 215-b-115
In an inert-atmosphere glovebox, monomer 2 (25 mg, 45.2 μmol; see SI, Section S2 for the 
synthesis of monomer 2) was dissolved in an anhydrous mixture of CHCl3/MeOH (9:1 v/v, 1 
mL) in a 20 mL scintillation vial equipped with a magnetic stir bar. A stock solution of 
Grubbs’ first-generation catalyst (5 mg) in CHCl3/MeOH (9:1 v/v, 5 mL) was prepared, a 
portion of which (2.48 mL, 3.01 μmol) was added to the vial containing the solution of 
monomer 2 under vigorous stirring. The resulting reaction mixture was stirred for 45 min at 
room temperature, at which time an aliquot (100 μL) was removed and quenched with 
excess ethyl vinyl ether. A portion of this quenched aliquot was evaporated to dryness, 
redissolved in CDCl3, and analyzed by 1H NMR spectroscopy, which indicated complete 
consumption of the monomer. The remaining portion was evaporated to dryness, dissolved 
in HPLC-grade THF, and subjected to GPC analysis (Mn = 9000 (theoretical Mn = 8000), 
PDI = 1.13).
Immediately after aliquot removal, a solution of monomer 1 (see SI, Section S1, 30.7 mg, 
45.2 μmol) in CHCl3/MeOH (9:1 v/v, 1 mL) was added to the reaction vial and the resulting 
polymerization mixture was stirred for an additional 45 min before being terminated with 
the addition of ethyl vinyl ether (1 mL). The reaction mixture was added quickly into 
vigorously stirred cold (−10 °C) pentanes (200 mL), and the resulting precipitate was 
isolated via vacuum-filtration and washed thoroughly with fresh pentanes to afford the 
product copolymer quantitatively as a red solid. See the SI for the 1H NMR spectrum, 
Section S3). Due to the lack of complete polymerization of monomer 1 when being initiated 
as the first block,7,31 we did not attempt to synthesize the reverse block copolymer 115-
b-215.
To maximize the number of chemical handles that can subsequently be used for surface 
functionalization of the PNPs, we employed a block copolymer with an equimolar ratio of 
monomers 2:1, while keeping the PNP diameter < 100 nm.
General procedure for the preparation of PNPs in the 60–75 nm size range
An aqueous suspension of the polymer nanoparticles was prepared by dialysis following a 
modification of the published procedure.7 An aliquot (2.5 mL) of a stock solution of block 
copolymer 215-b-115 (0.01 wt %) in DMSO was transferred to a 4 mL scintillation vial and 
stirred vigorously. Ultrapure deionized water was added to this stirring copolymer solution 
at a rate of 1 drop (50 μL, 1.75 wt %) every 1 s using a 20–100 μL micro-pipette until the 
mixture contained 18 wt % water. The resulting cloudy mixture was placed in a 3 mL 
dialysis cassette and dialyzed against ultrapure deionized water (500 mL), with the dialate 
changed every 2 h. Complete absence of DMSO in the dialysate after 48 h was verified by 
UV-vis spectroscopy as indicated by the disappearance of the UV cut-off for DMSO at 268 
nm.
Characterization of PNPs derived from block copolymer 215-b-115
DLS analysis of the final PNP aqueous suspension derived from block copolymer 215-b-115 
revealed relatively monodisperse PNPs with an average DH = 63 ± 7 nm and a PDI = 0.11 
(Figure 1B). TEM analysis indicated a uniform size distribution for the PNPs in the solid-
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state, with an average diameter of ~65 nm (Figure 1C) that is consistent with the DLS data. 
The zeta potential of these PNPs was determined to be −6.83 ± 0.5 mV. The average 
concentration of PNP particles is ~ 1 × 1010 particles/mL, as determined by NTA. The 
doxorubicin loading for the PNPs is 64 wt %, as calculated based on the doxorubicin wt% in 
the 215-b-115 copolymer.
DNA functionalization of doxorubicin-loaded PNPs and characterization data
In a 1.5 mL safe-lock Eppendorf tube, solutions of N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC•HCl, final concentration in reaction solution = 5 
μM) and N-hydroxysulfosuccinimide (sulfo-NHS, final concentration in reaction solution = 
7.5 μM) in ultrapure deionized water were added to an aliquot (1 mL) of the carboxy-
functionalized PNP suspension (1 × 1010 particles/mL, ~125,000 carboxylate groups) 
derived from the desired block copolymer. The reaction mixture was agitated (1000 rpm) on 
a multi-therm platform shaker (Benchmark Scientific, Inc., South Plainfield, NJ, USA) for 5 
min at room temperature. A freshly prepared aliquot of 3′-amino-terminated 
oligonucleotides (100 μL of a 10 μM solution) was then added to the reaction mixture, and 
the resulting mixture was covered with aluminum foil and agitated on a multi-therm 
platform shaker for 4 h at room temperature.
To increase the density of oligonucleotide packing on the PNP surface, EDC and NHS 
solutions (to 5 μM and 7.5 μM final concentrations, respectively, assuming that all the 
initially added reagents have been consumed/decomposed) were added to the PNP solution, 
and the resulting mixture was subjected to a salt-aging process.32 Aliquots of NaCl (8 μL of 
a 5 M solution to attain a final [NaCl] = 50 mM) were added to the reaction mixture every 
30 min, and the Eppendorf tube was sonicated for 15 s (Branson 2510 ultrasonic cleaner, 
Branson Ultrasonics, Danbury, CT, USA) after each salt addition. Upon reaching a total 
NaCl concentration of 300 mM, the reaction mixture was agitated on a multi-therm platform 
shaker for an additional 12 h at room temperature. The resulting PSNAs were then purified 
using size-exclusion chromatography (Sepharose CL-4B, Sigma Aldrich). The average 
concentration of PSNA particles was ~ 109/mL, as determined by NTA.
Characterization of oligonucleotides-conjugated doxorubicin-loaded PNPs
DLS analysis of the final DNA-functionalized PNP aqueous suspension derived from block 
copolymer 315-b-515 revealed relatively monodisperse PNPs with an average DH = 88 ± 3 
nm and a PDI = 0.13. The zeta potential of the oligonucleotide-modified PNPs was 
determined to be −31.2 ± 3.2, indicating that negatively charged oligonucleotides are 
conjugated to the PNP surface. For TEM analysis, the PNPs were pre-stained with uranyl 
acetate solution (10 μL, 2% w/v).
Quantification of oligonucleotides strands on the surface of PSNAs
To assess the degree of oligonucleotide surface modification, an aliquot (20 μL) of the 
purified Cy5-oligonucleotide-modified PNPs was added to DMSO solution and placed on a 
multi-therm shaker for 2 h at 37 °C to dissolve the PSNAs. An aliquot (50 μL) of the 
resulting solution was further mixed with DMSO (final volume = 200 μL), and its 
fluorescence at the emission wavelength of Cy5 (λex = 649 nm, λem = 670 nm) was 
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recorded using a Synergy HT multi-mode microplate reader (BioTek, Winooski, VT, USA). 
This fluorescence was compared against a calibration curve constructed from absorbance 
values for solutions of the Cy5-labeled oligonucleotides in DMSO (concentrations = 0, 0.1, 
0.25, 0.5,1, 2.5, 5 μM). From this analysis and the number of PSNA nanoparticles in 
solution (obtained from NTA), each cholesterol-containing PSNA particle was estimated to 
have ~1900 oligonucleotides strands and each doxorubicin-loaded PSNA particle was 
estimated to have ~1200 oligonucleotides strands. The doxorubicin loading is 63.8 wt %, as 
calculated based on the doxubicin wt % in the 215-b-115 copolymer and the total weight of 
the DNA, assuming an average density of 1 for the whole construct.
Stability study of PNPs and PSNAs
Two separate aliquots of the doxorubicin-containing PNPs and PSNAs (500 μL) were 
transferred to a 1.5 mL safe-lock Eppendorf tube and centrifuged for 30 min at 10K rpm to a 
solid pellet. The supernatant was removed and the PNPs were re-suspended in PBS (500 μL, 
10 mM, pH 7.4, 150 mM [NaCl]). As expected, characterization of the PNP suspension in 
PBS resulted in loss of the original well-defined morphology of the parent PNPs as observed 
by TEM and DLS. The size of PSNAs was analysed periodically over a two month period 
using DLS. We note in passing that while single-stranded DNA has been adsorbed to the 
surface of polymer nanoparticles through non-covalent modification,33,34 such constructs 
have not been tested for stability in cell culture media.
Melt Analysis
Melt analysis experiments were carried out using a Cary 5000 UV-vis spectrometer 
equipped with a programmable heating stage (ThermoFisher Scientific, Carlsbad, CA, 
USA). Doxorubicin-containing PSNAs functionalized with Melt A strands were prepared as 
described above. 13 nm Au-core SNAs functionalized with the complementary Melt B 
strands (Table S1) were prepared following literature protocols.32 The aggregates were 
formed by combining these two materials in a 1:1 ratio (total DNA concentration = 1.5 μM, 
total volume = 1 mL). The aggregates were then subjected to a temperature ramp from 20 to 
65 °C (rate of 0.25 °C/min) while the absorbance for the aggregates was continuously 
monitored at 260 nm.
Cell culture experiments
SKOV-3 cells were purchased from American Tissue Culture Collection (ATCC, Manassas, 
VA, USA) and grown in McCoy’s 5A medium (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% heat-inactivated fetal bovine serum, penicillin (100 IU/mL), and 
streptomycin (50 μg/mL) and maintained at 37 °C with 5% CO2 as per ATCC instructions. 
For cellular studies, the cells were plated at 60% confluency 24 h prior to the treatment.
Confocal microscopy of PSNAs
In a typical experiment, SKOV-3 cells were plated on a 35 mm FluoroDish (World Precision 
Instruments, Saratosa, FL, USA) and incubated for 24 h before being transfected with the 
appropriate oligonucleotide formulation (final DNA concentration = 0.1 μM). The treated 
cells were incubated for 24 h before being washed three times with 1× phosphate-buffered 
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saline (PBS, Invitrogen) and imaged under a Zeiss LSM 510 inverted laser-scanning 
confocal microscope using Hoechst 33342 as a nuclear stain. The fluorescence excitation for 
Cy5 was set as 630 nm and emission 650–710 nm. For Z-stack images, the images were 
collected in different planes with a depth of 0.3 μM.
Cellular uptake experiments
The cellular uptake of the PSNAs was compared to that of the free drug in SKOV3 cells. In 
preparation for this analysis, the cells were seeded at 60% confluency in a 96 well plate 24 h 
before treatment with PSNAs and free doxorubicin. The treatments were carried out at 0.1, 
0.5, 1, and 2.5 μM of doxorubicin. The cells were then incubated with either free drug or the 
PSNAs for 24 h before washing three times with 1× PBS. The cells were then detached from 
the plate surface by exposing to trypsin (20 μL) for 5 mins and fixed using a 4 % para-
formaldehyde solution (in 1× PBS). The intracellular delivery of doxorubicin was quantified 
via flow cytometry on a Guava easyCyte 8HT instrument (Millipore, Billerica, MA, USA) 
using the doxorubicin channel and normalized based on the intensity of the untreated cells.
Cell viability studies for doxorubicin and Dox-PSNAs
SKOV-3 (ovarian cancer) cells were seeded in 96 well plates at a density of ~5000 cells per 
well 24 h before the experiment. Cells were incubated with a fixed amount (100 μL) of 
solution containing either doxorubicin or Dox-PSNAs that were prepared at varying 
concentrations in OptiMEM (Invitrogen) at 37 °C. After overnight incubation, the media 
was replaced with regular growth medium (McCoy’s 5A supplemented with 10% heat-
inactivated fetal bovine serum, penicillin (100 IU/mL), and streptomycin (50 μg/mL)), and 
the cells were incubated at 37 °C for an additional 48 h. Cell viability was assessed using the 
alamarBlue® cell viability assay (ThermoFisher Scientific, Carlsbad, CA, USA) according 
to the manufacturer’s recommended protocol. Briefly, 10% alamarBlue® reagent in regular 
growth medium was added to cells (100 μL per well), and the treated cell plate was 
incubated at 37 °C for 4 h before being analyzed on a Synergy H4 Multimode Microplate 
Reader. Fluorescence data at 570 nm were collected and normalized to that for an untreated 
control. Reported values represent the mean ± standard deviation of 5 replicates.
RESULTS AND DISCUSSION
As a general strategy,35 ROMP-based PNPs were assembled from short amphiphilic block 
copolymers consisting of one hydrophobic doxorubicin-conjugated block and a hydrophilic 
carboxy-terminated, poly(ethylene oxide) (PEO)-loaded block (Figure 1). With this design, 
the doxorubicin-loaded block constitutes the core of the PNPs, and the PEO-loaded segment 
forms a shell with terminal carboxy groups that can be used for further surface modification. 
The doxorubicin payload was linked to the hydrophobic segment through an acid-cleavable 
linkage,4 which can be released in the low-pH environment of the late endosome36 or in the 
tumor tissue.37
The amphiphilic block copolymers needed for PNP preparation were synthesized by block-
copolymerizing the carboxy-terminated, PEO-conjugated monomer 2 and the doxorubicin-
conjugated monomer 1 (Figure 1A). A 15:15 molar ratio for monomers 2:1 was chosen to 
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limit the molecular weight of the polymer < 45 kDa, thus facilitating renal clearance of the 
polymers post drug release.38 Monomer 2 was successfully homo-polymerized using 
Grubbs’ first-generation olefin metathesis ((PCy3)2Cl2Ru=CHPh) catalyst (3) as confirmed 
by 1H NMR spectroscopy and gel-permeation chromatography (GPC) analyses (Mn = 9000 
(theoretical Mn = 8000), polydispersity index (PDI) = 1.17; Supporting Information (SI), 
Section S2). Sequential addition of monomer 1 to the homo-polymerized block 215, 
followed by quenching with ethyl vinyl ether resulted in the formation of our desired 
monodisperse amphiphilic block copolymer 215-b-115 (final polymer Mn = 15000 
(theoretical Mn = 14000), PDI = 1.12; see Materials and Methods section and SI, Section 
S3).
Following our previously established strategy,7 dropwise addition of water to a DMSO 
solution of copolymer 215-b-115, followed by exhaustive dialysis against ultrapure deionized 
water, afforded an aqueous suspension of carboxy-functionalized, doxorubicin-loaded PNPs 
(Figure 1A). These nanoparticles have small hydrodynamic diameters (DH = 63 ± 7 nm, 
Figure 1B) and exhibit a narrow size distribution (PDI = 0.11 ± 0.02), as measured by 
dynamic light scattering (DLS). Transmission electron microscopy (TEM) also confirmed 
their homogeneous spherical morphology (Figure 1C) with an average DH of 65 ± 5 nm. 
Key to the realization of these small nanoparticle sizes was a fast rate of water addition over 
a shorter time period than previously reported7 (see Materials and Methods section).
The covalent surface modification of the carboxy-functionalized PNPs with 3′-amine-
terminated DNA was achieved using EDC/NHS coupling (Figure 1A). A mixture of the two 
components was stirred together with the EDC and NHS reagents for 4 h before being 
subjected to a salt-aging process to further increase the DNA density on the PNP surface32 
(see Materials and Methods section). After the total salt concentration reached 0.3 M, this 
mixture was allowed to react further overnight before being purified by size-exclusion 
chromatography. A TEM image (Figure 1D) of the isolated PSNA clearly shows the 
retention of the discrete and spherical morphology of the parent PNP (diameter ~ 87 nm). 
Their DLS-derived size distribution plot (Figure 1B) shows an increase in the hydrodynamic 
diameter (DH = 88 ± 3 nm and PDI = 0.13 ± 0.03) that can be attributed to the addition of a 
dense DNA shell on the PNP surfaces. The shift in zeta potential (−5.1 ± 1.5 mV for the 
parent PNPs) to a higher negative value (−31.2 ± 3.2 mV for the PSNAs) also corroborates 
the successful conjugation of DNA to the PNP surface. Notably, the presence of the DNA 
shell on the surface of the PNP can be clearly observed upon staining of the PSNAs with 
uranyl acetate (z-contrast and transmission modes; Figure 1D). While not a primary focus of 
the current work, the thickness of the DNA shell can be changed by altering the length and 
composition of the oligonucleotide strands.39 On average, ~1200 DNA strands/PNP were 
conjugated to the surface of each PNP as determined by fluorescence spectroscopy and 
nanoparticle tracking analysis (NTA) to quantify the number of PSNAs in a given sample via 
light scattering and Brownian motion. This DNA surface density (~7 pmol/cm2, see 
Materials and Methods section for calculation) is comparable to but slightly higher than the 
loadings obtained for our previously reported liposomal SNA constructs.40
The doxorubicin-loaded PSNAs show excellent stability in comparison to the parent PNPs, a 
property that enables their use in cellular systems. For example, the PSNAs remain 
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colloidally stable after 2 months of incubation in phosphate-buffered saline (1× PBS) at 
room temperature (Figure 2A). In contrast, subjecting the unmodified PNPs to the same 
treatment for only a week resulted in formation of polydisperse aggregates irreversibly 
agglomerated, presumably through interparticle fusion. Most relevant for physiological 
applications, no change was observed in the DLS distribution plot for the PSNAs after 3 
days of incubation at 37 °C in 1× PBS (Figures 2C and 2D). We attribute this enhanced 
stability to the electrostatic repulsion between the negatively charged oligonucleotides that 
comprise the shell of the PSNA, which inhibits particle-particle fusion under physiologically 
relevant conditions.18 Notably, Dox-PSNAs remain stable in the presence of human serum 
while still maintaining their acid-triggered drug-release properties.31 The doxorubicin-based 
fluorescence profiles for Dox-PSNAs after being incubated at 37 °C in PBS and human 
serum solution (10% v/v) are very similar as evidenced by minimal leakage of the drug (SI, 
Figure S8). In contrast, exposing Dox-PSNAs to 0.1 M HCl (aq) leads to a six-fold increase 
in drug release after one hour (SI, Figure S8).
Consistent with the assigned SNA structure, PSNAs cooperatively hybridize with 
complementary Au core SNAs. For example, when PSNAs were combined with 
complementary 13 nm Au-core SNAs (Figure 3A), visible aggregates can be observed and 
isolated. TEM analysis (Figures 3B and 3C) of these hybridized materials clearly shows a 
complete coverage of the larger PSNAs by the smaller Au-core SNAs. The increase in the 
melting temperature (Tm of the PNP-AuNP hybrid = 54.7 °C vs Tm = 52 °C (as calculated at 
150 mM NaCl and 1.5 uM oligonucleotides using IDT OligoAnalyzer41) for the free DNA 
duplex analog) of these aggregates and their narrow thermal denaturation profile (full width 
at half-maximum (fwhm) of the first derivative is ∼2.3 °C) confirms cooperative binding 
behavior that is characteristic of SNAs15 (Figure 3D).
As expected, the dense oligonucleotide shell of the Dox-PSNAs greatly facilitates their 
entrance into cells. As shown by confocal microscopy, SKOV-3 cells (ovarian cancer ascites) 
readily uptake Dox-PSNAs that were surface-modified with 5′-Cy5-labelled 
oligonucleotides (Figure 4A). This is in stark contrast to the non-functionalized PNP analog, 
which settles out of cell culture media due to aggregation and shows low and non-uniform 
uptake.31 Such enhanced cellular internalization of SNA structures has been attributed by 
Mirkin and coworkers to the interaction of the oligonucleotide shell with Class A scavenger 
receptors (SR-A) present on the cell surface, followed by caveolin-mediated endocytosis.23 
Because our goal was to enhance the delivery of the therapeutically active payload of Dox-
PSNAs to diseased cells, a generic T20 DNA sequence was sufficient for this purpose. We 
note in passing that although a detailed mechanistic study comprising competitive and 
endocytosis inhibition assays can be carried out to ascertain the exact uptake mechanism, 
such a study is beyond the scope of the present work.
The cellular internalization properties of the Dox-loaded PSNAs (Dox-PSNAs) lead to in-
vitro cytotoxicity against SKOV3 cancer cells that is comparable to that of free doxorubicin 
(Figure 4B). Such a study could not have been properly carried out with the parent PNPs due 
to their aggregation behavior in biological media. Indeed, PNPs have been observed to settle 
out of cell culture media over time, leading to low and non-uniform uptake in SKNSH wild-
type cells.31 The observed cytotoxicity of the Dox-PSNAs can be attributed to the acid-
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induced cleavage of the carbamate linkage between the block copolymer backbone and the 
doxorubicin, allowing for the release of the latter into the cytoplasm.6,31 Supporting this 
conclusion is the observation that the analogous PSNAs with cholesterol-loaded cores does 
not show any cytotoxicity against SKOV3 cells (SI, Section S5).
CONCLUSIONS
In summary, we have demonstrated that the successful modification of doxorubicin-loaded 
PNPs with a dense oligonucleotide shell greatly increases their colloidal stability in 
biological media under physiological conditions. The dense shell of oligonucleotides allows 
the resulting Dox-PSNAs to have enhanced cellular uptake, manifesting in cytotoxicity that 
is comparable to the free drug. Importantly, this SNA-based strategy should be generalizable 
to other therapeutic-loaded nanoparticles for in vivo applications in the treatment of cancer 
and other diseases.
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A) Synthesis of block copolymer 115-b-215 and subsequent formation of the corresponding 
PNPs. B) Dynamic light scattering (DLS) data for the PNPs before and after covalent DNA 
functionalization. C–D) TEM image of the PNPs before (C) and after (D) DNA 
functionalization.
Banga et al. Page 12






















A) Doxorubicin-loaded PSNAs remain stable for over two months in 1× PBS as analysed by 
TEM and DLS. B) Doxorubicin-loaded PNPs aggregate when incubated in 1× PBS for a 
week. C and D) DLS profiles for Dox-PSNAs confirming their stablity in 1× PBS at 37 °C 
for 3 days.
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A) A schematic drawing of the Dox-PSNAs hybridized to complementary 13 nm Au-core 
SNAs. B–C) TEM images of the Dox-PSNAs surrounded by complementary Au-core SNAs 
conjugates. Scale bar is 100 nm. D) The thermal denaturation profile (red) of the [Dox-
PSNAs + Au-core SNAs] hybridized aggregates monitored as a change in extinction at 260 
nm. The overlaid 1st derivative (blue) of this profile shows the sharp melting transition. See 
SI, section S10 for the control experiment.
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A) Confocal laser-scanning microscopy images of SKOV-3 cells that have been incubated 
for 24 h with free doxorubicin (Dox) and doxorubicin-loaded PSNAs (Dox-PSNAs) at 2.5 
μM Dox concentration. Given the qualitative nature of the confocal image (e.g., change in 
focal point between sample wells), the various signal intensities should not be compared 
across rows. In addition, each panel is limited to a few cells and do not represent the entire 
population. A statistically significant flow cytometry study (SI, Figure S10) does show 
higher doxorubicin fluorescence signal for the cells that have been incubated with free 
doxorubicin. B) Cytotoxicity profiles for SKOV-3 cells that have been incubated for 48 h 
with dox and Dox-PSNA formulations at 5 nM-10 μM [ Dox]. The similarity in toxicity 
between the doxorubicin-loaded NPs and free doxorubicin is not surprising given previous 
studies from our group,31,42 and the fact that IC50 measurements are highly dependent on 
many variables (treatment time, incubation time post-treatment, release of payload from the 
delivery vehicle, cell type and confluency) and can vary by several fold, depending on 
conditions.
Banga et al. Page 15






















The covalent surface modification of carboxy-functionalized PNPs with amine-terminated 
oligonucleotides (green) via amide-coupling chemistry.
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